Watch for the BLA submission in 2027 and potential partnership or commercialization updates as Celldex transitions toward a commercial-stage organization. The sustained efficacy through 24 weeks and strong data in omalizumab-refractory patients support a differentiated label, which could drive peak sales estimates upward.
Price Chart
Executive Summary
Celldex reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria (CSU). Both trials met the primary endpoint (mean change in UAS7 at Week 12) and all key secondary endpoints with high statistical significance, including in omalizumab-refractory patients and those with severe angioedema. The company plans to submit a BLA to the FDA in 2027, positioning barzolvolimab as a potential best-in-disease therapy in a large unmet-need market.
Key Facts
- Both Phase 3 EMBARQ-CSU1 (n=963) and EMBARQ-CSU2 (n=976) met the primary endpoint of mean change in UAS7 at Week 12 with p<.00001 for both doses vs placebo.
- Complete response (UAS7=0) rates at Week 12: 42-46% for barzolvolimab vs 9-13% for placebo; at Week 24: 45-54% vs 15-18%.
- In omalizumab-refractory CSU, complete response at Week 12 reached 42-55% vs 9-15% for placebo (p≤.009).
- Complete resolution of angioedema (AAS7=0) at Week 12: 63-74% for barzolvolimab vs 34% for placebo (p<.00001).
- Safety profile was favorable and consistent with prior Phase 2 experience through 24 weeks.
- BLA submission to the FDA is planned for 2027.
Financial Impact
Positive Phase 3 data in a large CSU market (antihistamine-refractory CSU) with best-in-disease efficacy and a clear path to BLA in 2027; no financial figures provided in the filing.
Risk Factors
- Regulatory risk: BLA acceptance and FDA review timeline are uncertain.
- Competition from existing therapies (omalizumab, ligelizumab) and emerging oral agents.
- Commercial execution risk as Celldex builds out its commercial infrastructure.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-109465 |
| Document: tm2625892d1_8k.htm | 0001104659-26-109465 |
| Document: 0001104659-26-109465-index-headers.html | 0001104659-26-109465 |
| Document: 0001104659-26-109465-index.html | 0001104659-26-109465 |
| Document: 0001104659-26-109465.txt | 0001104659-26-109465 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G/A | $30.43 | awaiting T+60 | — | $30.08 (−1.17%) |
Sep 22, 2026 4w ago | Institutional Cluster | $33.51 | awaiting T+60 | — | $30.08 (−10.25%) |
Sep 22, 2026 5w ago | 8-K | $33.51 | awaiting T+60 | — | $30.08 (−10.25%) |
Sep 22, 2026 5w ago | Press Release | $33.51 | awaiting T+60 | — | $30.08 (−10.25%) |
Jun 14, 2026 19w ago | Press Release | $32.12 $38.10 | ▼ −18.62% | ▼ −18.22% | $30.08 (+6.37%) |
Jun 14, 2026 19w ago | Press Release | $32.12 $38.10 | ▲ +18.62% | ▲ +18.22% | $30.08 (−6.37%) |
Jun 11, 2026 19w ago | Institutional Cluster | $29.96 $39.12 | ▲ +30.57% | ▲ +26.75% | $30.08 (+0.38%) |
Jun 10, 2026 19w ago | Press Release | $29.96 $39.12 | ▲ +30.57% | ▲ +26.75% | $30.08 (+0.38%) |
May 7, 2026 24w ago | 8-K | $33.97 $39.05 | ▲ +14.95% | ▲ +10.11% | $30.08 (−11.47%) |
May 7, 2026 24w ago | Press Release | $33.97 $39.05 | ▲ +14.95% | ▲ +10.11% | $30.08 (−11.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers